Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on June 2, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Infinium EPIC v2 Methylation Kits

Closed
75N98026Q00497Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.
Triad - DOE Contractor

POSTED

2 days ago

DEADLINE

in 6 months
NAICS: 541714
New
Federal
Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.
Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day

AI Contract Overview

Show more

The contract involves the procurement of four Infinium Methylation EPIC v2 kits, each designed to process 96 samples, from the vendor. These kits are to be used specifically for a research study conducted by the Center for Research on Genomics and Global Health, which aims to investigate differential methylation patterns in a participant cohort. The methylation arrays, produced by Illumina, enable genome-wide methylation analysis and will be processed at the NHGRI Genomics Core using specialized equipment such as the Illumina iScan, Autoloader, and Tecan Liquid Handling Robot to ensure efficient and automated sample handling. The government is responsible for storing the kits under manufacturer-recommended environmental conditions and using them according to the prescribed instructions to maintain their integrity. This procurement is a one-time order expected to support genotyping activities completed within one year. The contract, posted by the National Institutes of Health at their Bethesda, Maryland location, is part of a presolicitation process with a response deadline set in June 2026. The goal is to facilitate high-quality methylation genotyping critical to the ongoing genomic research project sponsored by the Department of Health and Human Services.

General Info

Procurement of four Infinium Methylation EPIC v2 kits for genome-wide methylation analysis research.

Agency

Department Of Health And Human Services → National Institutes Of Health Olao

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

(1)

Requirements for Infinium Methylation EPIC v2 Kits

DOCXsow

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

Presolicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao
Contacts1 person available
OfficeBETHESDA, MD, 20892, USA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health Olao
Office AddressBETHESDA, MD, 20892, USA
Contacts

Full Description

Show more

Contractor Requirements: 


  1. The vendor shall provide (4) Infinium Methylation EPIC v2 kits (96-sample kits) 

Government Responsibilities: 


        2. At all times keep the genotyping kits will be stored in the environmental conditions recommended by the manufacturer. 



  1. Use the genotyping kits in accordance with such instructions and recommendations relating to care and operation as may be issued by the manufacturer. 
  2. Background: 
  3. The Center for Research on Genomics and Global Health is conducting a study to explore the differential methylation among a cohort of individuals using Illumina’s Infinium Methylation EPIC v2 beadchip kits. 
  4. Purpose and Objectives: 
  5. This order is for methylation arrays produced and manufactured by Illumina. These beadchips are designed specifically for studying methylation changes across the genome. The methylation beadchips will be implemented as part of a study conducted by the Center for Research on Genomics and Global Health exploring methylation status of genes among participants previously recruited. The methylation genotypes will be generated by the NHGRI Genomics Core which has the necessary equipment and expertise for efficient processing of Illumina SNP beadchips.  The Core has an Illumina iScan, Illumina Autoloader, and a Tecan Liquid Handling Robot for automated processing of samples. 
  6. This is a one-time-use product, and the genotyping is expected to be completed within 1-year.